38 search results for: type 2 inflammation

Itch in AD, PN and CSU: Role of <b>Type</b> <b>2</b> <b>Inflammation</b>

expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

27 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

UCARE <b>2</b>0<b>2</b>3: Potential Role of <b>Type</b> <b>2</b> Cytokines in CSU Pathogenesis

expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

2 min

Dermatology

Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.

<b>Type</b> <b>2</b> <b>Inflammation</b> Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

Contribution of <b>Type</b> <b>2</b> Cytokines to <b>Inflammation</b> and Itch in AD, PN, and CSU

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

expert video

Mast Cells and the Neuroimmune Axis in CSU

10 min

Dermatology

A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.

expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

11 min

Dermatology

A review of the neuroimmune axis and the mechanisms involved in perpetuating chronic itch in AD, PN, and CSU.

Neuroimmune Axis and Neuro<b>inflammation</b> in PN

expert video

Neuroimmune Axis and Neuroinflammation in PN

11 min

Dermatology

A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.

expert video

Neuroimmune Axis in Atopic Dermatitis

8 min

Dermatology

A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

5 min

Dermatology

An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.

Differences in Manifestations of <b>Type</b> <b>2</b> Inflammatory Diseases

expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

2 min

Dermatology

Dr. Brian Kim highlights the differences in manifestation of type 2 inflammatory diseases.

The Disease Burden of AD in Children and the Impact of <b>Type</b> <b>2</b> Comorbidities

expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

12 min

Dermatology

Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region